Cosentyx
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
April 27, 2023Business Services CHMP, Cosentyx, Dermatology, Novartis
Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …
Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis
August 3, 2020Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis
Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients …
UCB’s investigational IL-17A and IL-17F inhibitor outclasses Novartis’ Cosentyx in plaque psoriasis
July 24, 2020Medical Communications, Research and Development Cosentyx, UCB, pharma, psoriasis
UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …
Novartis’ Cosentyx hits primary goal in Phase 3 non-radiographic axial spondyloarthritis study
June 4, 2020Research and Development Cosentyx, Novartis, axial spondyloarthritis
New Phase 3 data has been released on the efficacy of Novartis’ interleukin (IL)-17A inhibitor Cosentyx (secukinumab), showing that the …
EU approval for Novartis’ Cosentyx in active non-radiographic axial spondyloarthritis
April 29, 2020Research and Development, Sales and Marketing Cosentyx, EU, Novartis, axial spondyloarthritis, pharma
Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial …
AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance
January 16, 2020Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis
AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …
Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis
November 1, 2019Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma
Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …
Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows
October 10, 2019Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis
Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
Novartis’ Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis
September 17, 2019Manufacturing and Production, Research and Development Cosentyx, Novartis, pharma
Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx …
Novartis provides promising update on Cosentyx in plaque psoriasis
June 26, 2019Research and Development Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that …
Novartis’ Cosentyx approved in China for plaque psoriasis
April 2, 2019Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …
Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial
March 5, 2019Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis
New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …
Novartis doubles down on Cosentyx’s efficacy in psoriasis with extensive real-world data
September 13, 2018Research and Development Cosentyx, Novartis, pharma, psoriasis
Novartis was yet another company to reveal new data on a psoriasis drug at the European Academy of Dermatology and …
Lilly posts promising P3 Taltz data
February 14, 2018Research and Development Cosentyx, Eli Lilly, IL-17, Novartis, Taltz, biotech, drugs, pharma, pharmaceutical
The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …
Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis
January 16, 2018Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma
Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …
Latest content
Five Facts about cardiovascular disease
